Abbott To Pay $52M To Norvir Direct Purchaser Class

Law360, New York (April 8, 2011, 7:18 PM EDT) -- Abbott Laboratories agreed in a California federal court on Friday to pay direct purchasers of its HIV drugs Norvir and Kaletra $52 million to resolve a consolidated antitrust class action.

The direct purchasers filed a motion urging the U.S. District Court for the Northern District of California to approve the $52 million deal, which resolves the direct purchasers' allegations that Abbott tried to use its monopoly on Norvir to protect its flagging monopoly power with respect to Kaletra.

Abbott announced in March that it had reached...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.